60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]

Read More

August 15th, 2018

China’s dynamism requires a nimble CRO with extensive research networks

China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s most populous nation (and second largest economy) continues to mature, so does their regulatory requirements. These regulatory adjustments pose a risk to sponsors […]

Read More

December 15th, 2016

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network